ArticleFrontiers in pharmacology2023

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks.

Shen Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.